7.5 dose tirzepatide TrimRX Zepbound 7.5 mg/0.5 mL injection

Remind yourself that: Your worth is not defined by your weight

PLoS One 2010;5(7):e11749

The following timeline, based on clinical trial data from Eli Lilly, shows the typical progression: Appetite suppression typically begins around day 3 of the first dose, with significant feelings of fullness developing by week 2

MHRA-approved and NICE-recommended options include semaglutide (Wegovy) and tirzepatide (Mounjaro), both available through NHS specialist weight management services or regulated private clinics for eligible patients with obesity and relevant comorbidities

These insights may help provide context for provider-patient conversations about expected treatment trajectory, though genetic predisposition does not determine exact medication response or guarantee outcomes

its not the drug which provides the benefits - it is the loss of weight which does so